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Abstract
Background: Pituitary stalk thickening (PST) used as an imaging diagnosis plays a major role in diagnosis and treatment
of the hypothalamus and pituitary disease at an early stage. Up until now, several lines of systematic investigations have
been conducted among adolescents, and the results indicated that PST is possibly one of the principal early
manifestations of sellar region tumor. To characterize the major clinical features of PST and to identify the
most effective treatments we conducted this study.
Methods: This was a retrospective review of patients with PST evaluated at Huashan Hospital over an eight-year period
between 2007 and 2014. One hundred fifty nine patients who were diagnosed PST were included. The data including
demographics, clinical presentations, imaging examinations, laboratory results and surgery were thoroughly reviewed
and carefully analyzed. According to their clinical presentations and examinations, relevant treatments were adopted and
different prognosis were observed.
Results: Of the 159 patients, 57 were males and 102 were females (median age was 29 and 43.4% were under the age
of 21 years). And of the patients in the age group between 30 and 35 years, 84% were females. “Polydipsia and polyuria”
was the most common clinical manifestation observed in 90 cases (>50%). 49.5% of the patients were diagnosed to have
at least one anterior pituitary dysfunction. The sellar region MRI (SR-MRI) data showed that patients who had different
clinical presentations or pituitary function showed different SR-MRI appearance. Over 60% patients who performed follow-
up MRI showed shrunken PST. Fourteen cases who received radiotherapy appeared to be improved as shown by MRI.
Conclusions: PST is most commonly seen in the teenagers and the women of reproductive age. Distinct etiology may
be identified based on the clinical manifestations, age and SR-MRI, which would help to make the final decision for
treatments. Radiotherapy and immuno-suppressed therapy are effective in alleviating clinical symptoms and shrinking
the stalk thickening.
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Background
Pituitary stalk thickening (PST) is an imaging diagnosis
defined as pituitary stalk diameter above 3.5 mm on sellar
region magnetic resonance imaging (SR-MRI) [1, 2].
Pituitary stalk lesion has a broad range of etiological
spectrum which can be categorized into three major
groups: congenital disease, inflammatory disease, tumor
and a multitude of subgroups [3]. And previous studies
have suggested that PST is possibly one of the principal
early manifestations of sellar region tumor, which is com-
monly found in children and young adults [4, 5]. However
a single mainstream modality of effective treatment has
not yet been established and clinical diagnosis is often
formed merely on the basis of clinical presentations and
imaging findings. Herein we reviewed our Huashan Hos-
pital experience with PST.
Methods
Patient demographics and case selection
We conducted a retrospective review of 197 patients
with pituitary stalk lesions evaluated at Huashan Hos-
pital from 2007 to 2014. Of these patients, 38 cases were
excluded due to lack of clinical data. Among the 159
cases included, 102 were women and 57 were male. The
average age was 27.6 years ranging from 2 to 80 years
(Fig. 1). It is particularly worth mentioning that young
patients under 21 years account for as much as 43.4%
(69 cases). In female, most patients fell to two age
Fig. 1 The distribution of demographics data at diagnosis. a shows two peak among age 10–15 and age 30–35, and in b male has only one
peak among age 10–15 while female distributes two peak
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groups including 15 to 20 yr and 30 to 35 yr. However,
in male, most patients were at 15- to 20-age group.
Diagnosis
We reviewed all available demographical, clinical evalu-
ation and physical examination data. The first SR-MRIs
from the patients were used to identify pituitary stalk ab-
normality. In addition, a broad array of endocrine func-
tions were evaluated including thyroid stimulating
hormone (TSH), free triiodothyronine (FT3), free thy-
roxine (FT4), fludrocortisol (F)(8 am), adrenocorticotro-
pic hormone (ACTH)(8 am), urinary free cortisol (UFC),
growth hormone (GH), insulin-like growth factor type 1
(IGF-1), luteotropic hormone (LH), follicle-stimulating
hormone (FSH), estraliol (E2), progesterone (P), testos-
terone (T), prolactin (PRL), 24 h urine volume, blood
osmolality and urine osmolality. Furthermore, regular
follow-ups (annual evaluation of clinical presentation,
physical examination, pituitary function and SR-MRI) of
these patients provided important comparative evi-
dences. And finally we collected 76 follow-up cases (5.9
± 3.2 yr, range from 2–18 years). In addition to the clin-
ical evaluation and follow-ups, we obtained also biopsy
and surgery data from nine patients.
Evaluation of pituitary function
Anterior hormonal deficiencies were diagnosed based on
low levels of serum hormones. In patients with adrenal
insufficiency, the insulin tolerance test (ITT) was used
for confirmation. As for the ITT, F < 18ug/dl was diag-
nosed adrenal insufficiency [6]. GH and IGF-1 were
measured in 31 patients and some of them have done
confirmatory tests. Diabetes insipidus (DI) was diag-
nosed by typical signs and symptoms, and were docu-
mented with the serum and urinary osmolarity; water
deprivation tests were performed in 30 patients.
Treatment modalities
Once diagnosed PST, patients received one of the three
treatment modalities, including symptomatic treatment
(mainly refer to the improvement of polyuria), radiother-
apy (Gamma Knife) or immuno-suppressed therapy
(using oral glucocorticoid, usually methylprednisolone
1.0 mg/kg*8 weeks). Different treatment was made ac-
cording to clinical presentations, endocrinology evalu-
ation, SR-MRI, together with patients’ willingness [7, 8].
And the effect was depended on follow-up SR-MRI.
However thinking of the risk of biopsy and the medical
condition in China, some clinical data were lost.
Statistics
One-sample Kolmogorov-Smirnov Test was used to con-
firm a normal distribution of the data. Mean ± SD was
used to describe normal distribution data, whereas median
and quartile were used to describe abnormal distribution
data. The paired t test was used to compare means of con-
tinuous variables. Chi-square test was used to compare
the difference between categorical variables. A value of
P ≤ 0.05 was considered statistically significant.
Results
Clinical manifestation
Of all presenting symptoms, polydipsia and polyuria
were the most common ones, which presented in 90
cases (56.6%) (Fig. 2).The second major symptom was
menstrual disorder in females (35 cases out of 37), while
male would complain of losing libido, which indicating
gonadal deficiency. Growth disorder was documented in
8 cases (about 5%, also accounted for 11.5% in children
population). The other 15 patients claimed to experience
symptoms such as headache or diplopia. It is worth not-
ing that 16 patients who had polydipsia and polyuria ex-
perienced other symptoms as well. Of those, eight had
gonadal dysfunction, three had growth disorder, one had
headache and four had other symptoms.
Pituitary functional evaluation
The assessment of anterior pituitary function was avail-
able in 91 patients (Table 1). Blood prolactin was ele-
vated in 33 of 79 patients (42%).
Adrenal insufficiency was found to be present in 24 of
69 patients (34.8%). Of the 78 patients whose thyroid
function was examined, deficiency was presented in 15
cases. Evaluation of gonadal function was performed in
70 patients, which showed that 26 of them had gonadal
deficiency. As for growth hormone (GH) secretion, 31
patients received evaluation and almost half of them were
diagnosed to have GH deficiency (45.2%). Of all patients,
45 (49.5%) had at least one deficient anterior pituitary axis
and 13 of them had deficiency in two or more axes.
Fig. 2 The clinical manifestation of PST patients. Among the five most-
seen clinical manifestation, polydipsia and polyuria accouts for the most,
and there is no difference between men and women. The second major
symptom was gonadal deficiency, which is more commonly seen
in women
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Ninety patients who claimed to have the symptom of
polydipsia and polyuria were analyzed. Based on their clin-
ical presentations along with urine and plasma osmolality,
60 patients were diagnosed as diabetes insipidus, while 16
of them also presented with anterior pituitary dysfunction.
Of the 30 patients who had water deprivation test, 25 of
them were diagnosed as complete central diabetes insipi-
dus and five as partial central diabetes insipidus.
SR-MRI findings and follow-up data
For all 159 patients who underwent their initial SR-
MRIs at our hospital, we divided them into three groups:
single pituitary stalk thickened, PST with enlarged pituit-
ary gland, PST together with other suprasellar lesion
(each group accounts for 55.3, 32.1 and 12.6% separ-
ately) (Fig. 3). And we also try to analyse the relationship
between SR-MRI and clinical presentations or pituitary
Table 1 hormonal evaluation in PST
Cases Percentage(%)
Adrenal Axis dysfunction 24 34.8
Thyroid Axis dysfunction 15 19.2
Gonadal Axis dysfunction 26 37.1
GH Axis dysfunction 14 45.2
Hyperprolactinemia 33 41.8
Fig. 3 Different SR-MRI appearance. There were three different SR-MRI appearances: a single pituitary stalk thickened, b PST with enlarged pituitary
gland, c PST together with other suprasellar lesion
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function (Fig. 4). Patients with enlarged pituitary gland was
more likely to have gonadal deficiency, meanwhile single
PST and PST together with suprasellar lesion appeared to
have posterior pituitary gland appearance with/without
anterior pituitary deficiency (especially growth disorder).
Therefore, we conducted regular follow-ups, and col-
lected 44 post-treatment MRI recordings. The follow-up
imaging demonstrated that PSTs in 27 cases (61.4%) of
the patients shrunk, 12 remained unchanged and only
five enlarged.
Treatment modalities and follow up
Among all the follow-up patients (Fig. 5), 5 of the 44
patients didn’t receive any treatment but underwent
regular follow-up from 6 to 60 months. Surprisingly,
their SR-MRIs didn’t indicate any noticeable develop-
ment of PST. And the other patients received one of the
three treatment modalities, including symptomatic treat-
ment, radiotherapy or immuno-suppressed therapy. Of
the 20 patients who received symptomatic treatment,
the thickness of pituitary stalks were decreased in nearly
half of them (nine cases), unaltered in six patients and
increased in five patients.
Nineteen patients received either radiotherapy (14
cases) or immuno-suppressed therapy (five cases). All 14
patients receiving radiotherapy showed shrinkage in the
thickness of pituitary stalk. Among five cases receiving
immuno-suppressed therapy, four cases showed shrink-
age while one case showed no change.
Finally, nine patients who underwent either surgeries
or surgical biopsy were followed up. All these nine pa-
tients presented with polyuria and polydipsia (two of
which also have amenorrhea, one together with body
weight gain and one with growth disorder). Of all the
patients, conspicuous mass was seen on SR-MRI in five
cases, persistent enhancement was reported in three
cases, and one patient underwent a biopsy of his rib first
and later PST was discovered. Pathological examination
reported 3 germinoma, 3 Langerhans cell histiocytosis
(LCH), one pituicytoma, one granular cell tumor and
one chronic inflammation. Patients were given subse-
quent treatment, however given the time this report has
been written, it is too early to obtain any post-surgery
MRI from these nine patients (Table 2).
Discussion
Up till now, very few reports have shared experiences in
dealing with PST patients. We therefore conducted this
retrospective case review in order to characterize its
various facets of imaging characteristics and clinical
manifestations, and gain a better understanding of the
differential effects of available treatments.
In our cohort, the average age of PST patients was
27.6 years and 43.4% of the patients were aged under
Fig. 4 Relationship between SR-MRI and clinical presentations or pituitary function. a: MRI findings and clinical presentations. b: MRI findings and
pituitary function
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21 yr, which strongly suggested the fact that PST is
mostly seen in the young adults and teenagers.
This result is to some extent in agreement with the ev-
idences shown in a number of previous reports [9–11],
which stated that patients with PST were mostly be-
tween 7 and 13 years old.
However, another recent review [12] reported an
average age around 44 years old in patients with PST.
Such difference may result from distinct patient
groups, as this report reviewed specifically the adult
population.
Indeed, another study [13] reported 37 cases of PST
together with central diabetes insipidus (CDI) and
showed that the average age at initial diagnosis is
29 years old, which is similar to our cohort.
Additionally, females accounted for over 84% in the
age group between 30 and 35 years, which was indicative
of the fact that women in their childbearing age are sus-
ceptible to PST.
Clinical manifestations such as polyuria and polydipsia
are the major reasons that patients see a physician at the
first place. In Fig. 2 the five most common clinical mani-
festations were shown in our PST patients, which include
polyuria and polydipsia, gonadal disorder (amenorrhea in
female or loss of libido in male in our context), growth
disorder, headache as well as diplopia (a sign of lesion
enlargement).
It is worth noting that these manifestations distribute
differently in the various age groups. Polyuria together
with polydipsia and growth disorder are more commonly
seen in teenagers whereas headache or diplopia are often
complained by the middle-aged patients.
An explanation for such different manifestations may
lie in the distinct underlying etiology. Headache or dip-
lopia is more common in the adult patients, mostly due
to the sellar mass as its enlargement could suppress
optic nerve [1]. In comparison, teenagers resort to the
physician mostly because of polyuria and polyuria which
are caused by germinoma or LCH [14].
To a clinical physician, it presents a great challenge to
make decision about effective treatment to individual pa-
tient without confirmed etiology. However, the age and
clinical manifestations can help to make decisions.
In 2007, Hamilton [1] reported 65 cases of pituitary
stalk lesions and they concluded that LCH and germi-
noma were the two dominant diseases that caused PST
in children, whereas the inflammatory was the number-
one disease that gave rise to PST in adult. Since the pub-
lication of this report, our decision-making process of
treating PST patients was biased in favor of the Hamil-
ton’s conclusions. More specifically, we strategically
Table 2 Cases who had surgeries or biopsies
Case Sex Age at diagnose Clinical presentation Diagnose
1 F 10 Polyuria and
growth disorder
Germinoma
2 M 35 polyuria Germinoma
3 F 21 polyuria Langerhans cell
histiocytosis
4 F 5 polyuria Germinoma
5 F 40 polyuria Granular cell tumor
6 M 45 polyuria Langerhans cell
histiocytosis
7 M 18 polyuria Langerhans cell
histiocytosis
8 F 10 polyuria and
amenorrhea
Chronic inflammatory
9 F 15 polyuria and
amenorrhea
Pituicytoma
Fig. 5 Different therapy and MRI changes. Five patients didn’t receive
any treatment but underwent regular follow-up didn’t indicate any
noticeable change. Of the 20 patients who received symptomatic
treatment, the thickness of pituitary stalks were decreased in nearly half
of them (nine cases), unaltered in six patients and increased in five
patients. All 14 patients receiving radiotherapy showed shrinkage in
the thickness of pituitary stalk. Among five cases receiving immuno-
suppressed therapy, four cases showed shrinkage while one case
showed no change
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divided patient groups by age, drawing a line at 35 years.
On one hand, it is widely acknowledged that both germi-
noma and LCH are sensitive to radiotherapy, for that
reason we administered radiotherapy to all 12 patients
under 21y as well as two adults under 35. It turned out
to be effective. On the other hand, we held the view that
most middle-aged patients are more likely to have in-
flammatory lesions and thus immuno-suppressed ther-
apy was administered to five patients above 35 years. It
worked in 4 patients. Besides, in our nine definitively-
diagnosed patients, five confirmed with either germi-
noma or LCH were under 35.
Additional remarks
PST is a rare disease and most of the clinical physicians
are not yet familiar with that. Towards making the final
decision of treatment and predicting future progression
of the disease, evaluation of anterior pituitary function
and sellar region MRI are two absolutely necessary pro-
cedures. In addition, the clinical manifestation and age
of the patients could play more important roles than
what we ever thought of before.
Nathan J. reported a remarkable discovery lately,
concluding that DI and anterior pituitary dysfunction
may sever as twin causal indicators to estimate in an
all-or-none fashion the likelihood of having neoplastic
process in PST patients [11]. Our results showed that
two-third of polydipsia and polyuria patients were
confirmed as diabetes insipidus and about half of the
patients were reported to have at least 1 anterior pi-
tuitary dysfunction who took the evaluation. Although
a causal interrelationship cannot be derived from
available weak statistical inference, there is emerging
evidence that clinical presentation together with im-
aging and functional evaluation could form a diagnos-
tic triangle to pin down the casual link between
symptoms and underlying pathologies. And our ex-
perience indeed surprised us that given supplementary
information from the clinical presentation, an early
PST onset combined with DI and hypopituitarism
helps make precise prediction about neoplasm. As for
neoplastic lesions, we recommend radiotherapy and
immuno-suppressed therapy is our first choice for fe-
male patients during their childbearing age.
We propose that a full picture of correlation between
PST and anterior pituitary function and the connection
to how they interact with clinical manifestation to con-
vey essential information to the physician in the
decision-making process, calls for a systematic clinic-
research data collection workflow. Once such workflow
becomes available, separately-scattered dots from three
diverged diagnostic approaches can converge to valu-
able inferences and lead to more effective treatment
strategies.
Conclusion
PST is most commonly seen in the teenagers in the ado-
lescence and the women in the childbearing ages. Dis-
tinct etiology may be identified purely based on the
dominant clinical manifestations in combination with
age, which in our case contributed markedly to the final
decision of treatments. Given our results, radiotherapy
and immuotherapy seem to work as the twin silver-
bullets, selectively alleviating clinical symptoms and
shrink the visible stalk thickening of two different
groups of patients.
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